ABOS · NASDAQ · Biotechnology

Acumen Pharmaceuticals (ABOS)

Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease.

$2.71
After hours+0.06 (+2.46%)
At close$2.65(+2.12%)